US OptionsDetailed Quotes
CYBN250117C2500
- 0.00
- 0.000.00%
15min DelayClose Jan 16 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover2284.12%IV-72.00%PremiumJan 17, 2025Expiry Date6.43Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9543Delta0.0094Gamma1.32Leverage Ratio-0.5389Theta0.0000Rho1.26Eff Leverage0.0004Vega
Cybin Stock Discussion
1 MINUTE AGO, 12:07 PM EST
VIA BUSINESSWIRE
Strategic Partnership Agreements will facilitate collaboration among sites, cultivate long term partnerships, enhance efficiency in trial operations, and improve overall site performance -
- First program member is Segal Trials, a preferred pr...
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Wednesday, 15th January at 12:07 pm
- Strategic Partnership Agreements will facilitate collaboration among sites, cultivate long term partnerships, enhance efficiency in trial operations, and improve overall site performance -
- First program member is Segal Trials, a preferred provider fo...
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
Monday, 13th January at 7:30 am
- Announced positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder ("MDD") -
- Initiated PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of MDD –
- Received U.S. Food and Drug Administration ("FDA") Breakthrough Therapy Designation ("BTD") for CYB003 for the Adjunc...
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
Tuesday, 10th December at 7:30 am
- Poster presentations highlight clinical data across Cybin's CYB003 deuterated psilocin and DMT programs -
Cybin Inc. (NYSE: CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new...
PHOENIXVILLE, Pa., Dec. 4, 2024 /PRNewswire/ -- Facet Life Sciences, a leader in US regulatory strategy and product development solutions for the life sciences industry, has been named as the US regulatory partner for Cybin Inc. ("Cybin"), a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative treatment options to address the large unmet need for people ...
CCORF Maintains Cybin(CYBN.US) With Buy Rating, Maintains Target Price $86
trading under 12 now seems like something is in the works.
$Vertex Pharmaceuticals (VRTX.US)$ $Astera Labs (ALAB.US)$ $Emergent BioSolutions (EBS.US)$
No comment yet